Drugs / dolasetron
dolasetron
also known as
Dolasetron mesylate · ANZEMET · Dolasetron mesilate · Dolasetron mesilate monohydrate · Dolasetron mesylate anhydrous · Dolasetron mesylate monohydrate · Dolasetron methanesulfonate · MDL 73,147EF
Small molecule targets HTR3A via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ANZEMET | — | 1997-09-11 | fda.gov ↗ |
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00511823 | Jul → Sep 2007 | chemotherapy-induced toxicity | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00020657 | Jul 2001 → Oct 2004 | cancer of unknown primary site | Gary Morrow | Completed | Missed primary |
| Comparator or background therapy8 trials | ||||||
| Phase 2 | NCT06593782 Comparator | Sep 2024 → Jun 2025 overdue | chemotherapy-induced toxicity | First Affiliated Hospital of Wenzhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT00003817 Background | Oct 1999 → Jul 2001 | cancer of unknown primary site | Gary Morrow | Completed | No outcome recorded |
| Phase 3 | NCT00820326 Comparator | Mar 2004 → Jun 2008 | fibromyalgia | University Hospital, Limoges | Completed | No outcome recorded |
| Phase 4 | NCT04817189 Comparator | Feb 2021 → Jul 2024 | chemotherapy-induced toxicity | Helsinn Healthcare SA | Completed | Met primary |
| Phase 4 | NCT01636947 Background | Dec 2012 → Aug 2014 | — | Merck Sharp & Dohme LLC | Completed | Missed primary |
| — | NCT07515027 Background | Apr → Nov 2026 expected | — | Shanghai Chest Hospital | Recruiting | No outcome recorded |
| — | NCT02625181 Background | Jul 2016 → Nov 2017 | — | Vanderbilt University | Completed | No outcome recorded |
| — | NCT02550119 Background | Apr 2006 → Apr 2010 | digestive system cancer | University of Southern California | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dolasetron | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00820326 ↗ |
| Known as | ANZEMET | “This study offers a new treatment, dolasetron or ANZEMET ®, which will be administered by intravenous way once a day during a 4 days Hospitalization.” NCT00820326 ↗ |
| Known as | Dolasetron mesilate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2368925 ↗ |
| Known as | Dolasetron mesilate monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2368925 ↗ |
| Known as | Dolasetron mesylate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02625181 ↗ |
| Known as | Dolasetron mesylate anhydrous | ChEMBL registry synonym — accepted as the source's own label CHEMBL2368925 ↗ |
| Known as | Dolasetron mesylate monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2368925 ↗ |
| Known as | Dolasetron methanesulfonate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2368925 ↗ |
| Known as | MDL 73,147EF | ChEMBL registry synonym — accepted as the source's own label CHEMBL2368925 ↗ |
| Action | Inhibit | “Patients receive their scheduled chemotherapy regimen containing doxorubicin and their scheduled oral 5 hydroxytryptamine 3 receptor antagonist antiemetic (ondansetron,...” NCT00020657 ↗1“Serotonin 3a (5-HT3a) receptor antagonist” CHEMBL2368925 ↗ |
| Modality | Small molecule | — CHEMBL2368925 ↗ |
| Route | Oral | “scheduled oral 5 hydroxytryptamine 3 receptor antagonist antiemetic (ondansetron, granisetron, tropisetron, or dolasetron mesylate)” NCT00020657 ↗ |
| Target | HTR3A | “Serotonin 3a (5-HT3a) receptor antagonist” CHEMBL2368925 ↗ |